Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes

AIM: To evaluate, using post hoc analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon‐like peptide‐1 receptor agonist, liraglutide (IDegLira), was consistently effective in patients with type 2 diabetes (T2D), regardless of the stage of T2D progression. METHOD...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Diabetes Obes Metab
मुख्य लेखकों: Rodbard, H. W., Buse, J. B., Woo, V., Vilsbøll, T., Langbakke, I. H., Kvist, K., Gough, S. C. L.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Blackwell Publishing Ltd 2016
विषय:
Original Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5063148/
https://ncbi.nlm.nih.gov/pubmed/26343931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12574
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन